VERICEL CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.94 USD | -1.86% |
|
+0.58% | +31.82% |
| Apr. 19 | Vericel Insider Sold Shares Worth $1,593,550, According to a Recent SEC Filing | MT |
| Mar. 15 | Vericel Insider Sold Shares Worth $1,552,075, According to a Recent SEC Filing | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- Sales forecast by analysts have been recently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 597.88 and 98.28 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +31.82% | 2.31B | C | ||
| -3.89% | 88.14B | A- | ||
| +1.45% | 40.51B | A- | ||
| -14.43% | 31.67B | B- | ||
| +51.20% | 24.62B | A | ||
| -14.85% | 15.65B | C | ||
| -13.87% | 12.07B | B- | ||
| -7.87% | 11.97B | D+ | ||
| -39.40% | 11.61B | B | ||
| +5.62% | 8.81B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- VCEL Stock
- Ratings Vericel Corporation